1. Home
  2. Supports
  3. Featured Project Solutions
  4. Universal Vaccine Solution

Universal Vaccine Solution

Creative Biolabs is dedicated to providing broadly neutralizing antibody (bnab) universal vaccine solutions, leveraging cutting-edge structural biology and immunology technologies to accelerate the development of next-generation universal vaccines against highly variable pathogens (such as influenza virus, HIV, etc.). We specialize in the discovery and engineering of critical epitopes targeted by bNAbs, the design of optimized immunogens, and comprehensive vaccine efficacy evaluation. Our goal is to help global clients overcome the limitations of conventional vaccines and develop innovative universal vaccines that offer durable, broad-spectrum protection to effectively address future pandemic challenges.

Talk to Our Vaccine Experts View Services
Representative image of the universal vaccine solution.

The Core of Universal Vaccine Solution

A broadly neutralizing antibody (bNAb) is an antibody capable of neutralizing multiple strains or even different species of the same pathogen. Universal vaccine development aims to induce the human body to produce such bNAbs, thereby achieving broad, durable immune protection against highly variable viral strains. The core of our bNAb universal vaccine solution lies in identifying the conserved epitopes targeted by these bNAbs (such as the fusion peptide of HIV or the hemagglutinin stem region of the influenza virus) and designing immunogens that guide the immune system to efficiently and specifically generate these critical antibodies.

Current Challenges: Difficulties in Inducing bNAbs

Low Immunogenicity of Conserved Epitopes

The conserved epitopes targeted by bNAbs are often hidden on the viral surface or possess low immunogenicity, making them difficult to effectively expose with conventional vaccines.

"Immunodominance Bias" Issue

The immune system tends to generate narrow-spectrum antibodies against the variable regions (the head) of the virus, rather than bNAbs targeting the conserved regions (the stem) required for universal protection.

Complex Engineering Design

Requires designing "minimal" or "chimeric" immunogens to overcome immunodominance bias, ensuring their structural stability and high purity.

Complexity of In Vivo Validation

Assessing whether the induced bNAbs truly possess broad protective power requires sophisticated in vitro neutralization assays and in vivo challenge models.

Creative Biolabs bNAb Universal Vaccine Solution

We provide a comprehensive, one-stop broadly neutralizing antibody universal vaccine solution service, covering target discovery through pre-clinical validation, designed to precisely address the key challenges in universal vaccine development.

Target Identification & Immunogen Design

Conserved Epitope Identification & Analysis: High-throughput sequence alignment and epitope conservation analysis. Epitope structure resolution combining crystallography and cryo-electron microscopy (Cryo-EM).

Immunogen Engineering Design & Optimization: Structure-based minimal immunogen design (e.g., stem-only design). Chimeric Immunogen construction to overcome immunodominance bias. Nanoparticle display platform construction for multivalent display of conserved epitopes.


Immunogen Preparation & Production

Recombinant protein expression and purification (suitable for various expression systems). Scalable preparation of virus-like particles (VLPs) or nanoparticles.

Immunization Strategy Optimization & Animal Models

Customized adjuvant screening and optimization. Immunization regimen design (Prime-boost strategies). Immunogenicity and protective efficacy evaluation in mouse, guinea pig, ferret, and non-human primate models.

Broad Neutralization Efficacy Evaluation

Comprehensive pseudovirus and live virus neutralization assays, covering major global strains. Antibody binding affinity and epitope specificity analysis (BLI/SPR).

Contact us for Detailed Service Items

Platforms and Technologies for the bNAb Universal Vaccine Solution

Schematic or experimental data of the structure-guided immunogen for universal vaccine development.

Structure-Guided Immunogen Design

Precisely design immunogens that specifically induce bNAbs, based on high-resolution antibody-antigen complex structures. This is central to achieving the bNAb Universal Vaccine Solution.

Process and outcome of high-throughput epitope mapping for universal vaccine design.

High-Throughput Epitope Mapping

Rapidly identify and clone B cells targeting conserved epitopes using next-generation sequencing (NGS), guiding immunogen modification.

Configuration and functional features of the custom nanoparticle display system for universal vaccine.

Custom Nanoparticle Display System

Utilizes ferritin, collagen, or synthetic nanoparticles to display conserved epitopes in high density and periodicity, significantly enhancing immunogenicity.

Setup and application of the in vitro neutralization assay platform for universal vaccine assessment.

In Vitro Neutralization Assay Platform

Equipped with P2/P3 lab capabilities to perform efficient and accurate broad neutralization activity testing against dozens or even hundreds of variant strains globally.

Standard Working Process for the bNAb Universal Vaccine Solution

Pathogen and Target Analysis

  • Select the target pathogen (e.g., pan-influenza, HIV, pan-coronavirus).
  • Utilize bioinformatics analysis to identify evolutionarily conserved, functionally critical surface antigen regions (bNAb epitopes).

Initial Immunogen Design & Synthesis

  • Design and construct candidate immunogens (e.g., monomers, multimers, chimeras) based on the target structure.
  • Perform small-scale expression, purification, and preliminary quality control.

Immunogenicity Assessment

  • Conduct initial immunization in small animal models.
  • Collect serum for ELISA, SPR/BLI analysis to verify antibody binding to the target conserved epitope.

Broad Neutralization Efficacy Verification

  • Perform pseudovirus or live virus neutralization assays.
  • Identify and isolate immunogens that successfully induced bNAbs.

Structural Optimization and Iteration

  • Resolve the structure of the bNAb-immunogen complex using the obtained bNAb.
  • Use structural information feedback to iteratively optimize the immunogen (e.g., modifying folding stability, hiding non-conserved epitopes).

Pre-clinical Candidate Selection & CMC

  • Determine the optimal adjuvant and immunization regimen.
  • Provide large-scale preparation and CMC (chemistry, manufacturing, and control) support to advance IND submission.
Partner with Creative Biolabs Now!

Creative Biolabs' Competitive Edge in the bNAb Universal Vaccine Solution

Structure-Driven Precision Design Capability

Our team of scientists is proficient in Cryo-EM and X-Ray crystallography, enabling nano-level precise active immunogen design to effectively avoid "immunodominance bias."

Diverse bNAb Epitope Library

Possesses industry-leading databases of bNAb sequences and target structures, accelerating the screening and validation of optimal conserved epitopes.

High-Standard Quality Control

Strict control over immunogen purity and structural integrity ensures that all prepared vaccine candidates meet high-throughput screening standards.

Comprehensive In Vitro Neutralization Assessment System

Established a platform for in vitro neutralization profile analysis covering hundreds of viral strains, providing the most rigorous broad protection data.

Key advantages of the proposed universal vaccine solution.

bNAb Universal Vaccine Solution Customer Feedback

"Creative Biolabs' structural design support in our universal influenza vaccine project was revolutionary. Their designed chimeric immunogen successfully increased our bNAb titer threefold, far exceeding expectations. Their broadly neutralizing antibody universal vaccine solution team is highly knowledgeable and responsive—a true partner."

- A VP of Vaccine R&D from a Major US Pharma Company

"We lacked the capabilities for non-human primate (NHP) model validation. Creative Biolabs not only provided comprehensive bNAb induction assessment, but their in vitro neutralization platform covered all the HIV strains we were interested in, saving us months of time. I highly recommend their broadly neutralizing antibody universal vaccine solution."

-A CEO from a European Biotech Startup

"Collaborating with Creative Biolabs on epitope mapping for highly variable viruses was an excellent experience. The high-quality Cryo-EM data they provided helped us quickly finalize the immunogen structure. Their technical proficiency demonstrates their leadership in the broadly neutralizing antibody universal vaccine solution field."

- A Principal Investigator from an Asian Academic Lab

Case Study

Universal Peptide-Based Vaccine for Canine Distemper Virus (CDV)

Background

CDV infects domestic/wild animals, with genome variations causing vaccine failure. Current vaccines use outdated strains, lack wildlife safety data, and have limited efficacy against circulating strains. The challenge was to develop a universal, safe vaccine for diverse CDV lineages.

Solution

Researchers used vaccinomics: built a peptide library from CDV H/F protein consensus sequences, predicted immunogenic peptides (CD4+/CD8+ T-cell, B-cell epitopes), and validated via molecular docking/dynamics with canine MHC (I/II) and TLR (2/4). They tested in silico (antigenicity/allergenicity) and in vitro (cytotoxicity/hemolysis) safety, then constructed a multiepitope polypeptide.

Results

12 peptides and the multiepitope polypeptide showed low cytotoxicity (≥80% cell viability) and hemolysis (<2%), non-toxicity, and antigenicity. The polypeptide interacted with TLRs, supporting broad immunity. It laid the groundwork for in vivo trials to protect domestic/wild animals from CDV.

Characterization results and safety validation data of the multiepitope polypeptide for universal vaccine.
Characteristics and Safety Validation of the Multiepitope Polypeptide.
Rendon-Marin, Santiago, and Julián Ruíz-Saenz. "Universal peptide-based potential vaccine design against canine distemper virus (CDV) using a vaccinomic approach." Scientific Reports 14.1 (2024): 16605. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41598-024-67781-5

Broadly Neutralizing Antibody Universal Vaccine Solution FAQs

Which pathogens are suitable for Creative Biolabs' Broadly Neutralizing Antibody Universal Vaccine Solution?

Our technology platform is highly versatile and mainly applicable to highly variable pathogens, including but not limited to: HIV-1, Influenza Virus, Coronaviruses, and other viruses and bacteria with highly glycosylated or variable surface antigens.

What is immunodominance bias, and how is it overcome in the bNAb universal vaccine solution?

Immunodominance Bias is the phenomenon where the immune system preferentially produces antibodies against the most accessible or abundant non-conserved regions of the virus, thereby suppressing the production of antibodies against the conserved regions. Our bNAb Universal Vaccine Solution overcomes this bias through structure-guided design and high-density nanoparticle display, which redirects the immune response to specifically focus on the conserved epitopes.

What makes your Broad Neutralization Efficacy Evaluation Platform unique?

Our platform includes customized Pseudovirus libraries and live virus strain libraries, allowing us to simultaneously perform neutralization assays against dozens or even hundreds of viral strains from different global locations and time points. We also provide antibody affinity and kinetic analysis using Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI) to ensure the accuracy and breadth of the results.

I already have a candidate immunogen; can you provide optimization services only?

Absolutely. Our bNAb Universal Vaccine Solution services can be flexibly combined based on client needs. We can specifically offer: a) Structural optimization and high-purity production of your immunogen; b) Comprehensive in vitro/in vivo immunogenicity assessment; and c) Screening of adjuvants and delivery systems.

How long does a typical project take, from target identification to pre-clinical candidate selection, using your bNAb Universal Vaccine Solution?

The project timeline depends on the complexity of the pathogen and the client's specific requirements. Generally, from conserved epitope identification to obtaining preliminary bNAb induction data, it takes approximately 6 to 12 months. Structural iterative optimization and comprehensive pre-clinical validation may require additional time. We provide detailed project plans and milestone management to ensure efficient progress.

Kickstart Your BNAb-Based Universal Vaccine Project

If you seek innovations for broadly neutralizing antibody universal vaccines or aim to speed up development, contact us. Our experts provide tailored solutions and pro support to fuel your project's success.

Contact Us
Online Inquiry

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


(USA)



Vaccine - Creative Biolabs
ISO 9001 Certified - Creative Biolabs Quality Management System
Shopping Basket